Novartis’ oral drug iptacopan tops injectables in head-to-head PNH trial

Novartis has chalked up another clinical trial win for its targeted factor B inhibitor iptacopan as it strives to position the drug as a patient-friendly, oral alternative to big-selling injectable rivals.